Basilea Pharmaceutica AG

LSE:0QNA Stock Report

Market Cap: CHF 505.5m

Basilea Pharmaceutica Valuation

Is 0QNA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0QNA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0QNA (CHF41.55) is trading below our estimate of fair value (CHF41.97)

Significantly Below Fair Value: 0QNA is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0QNA?

Key metric: As 0QNA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0QNA. This is calculated by dividing 0QNA's market cap by their current revenue.
What is 0QNA's PS Ratio?
PS Ratio3.4x
SalesCHF 149.02m
Market CapCHF 505.45m

Price to Sales Ratio vs Peers

How does 0QNA's PS Ratio compare to its peers?

The above table shows the PS ratio for 0QNA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.1x
OXB Oxford Biomedica
4.6x21.2%UK£451.5m
BVXP Bioventix
14.2xn/aUK£193.1m
GNS Genus
1.7x3.5%UK£1.1b
AVCT Avacta Group
7.8x0.4%UK£176.4m
0QNA Basilea Pharmaceutica
3.4x6.0%CHF 505.5m

Price-To-Sales vs Peers: 0QNA is good value based on its Price-To-Sales Ratio (3.4x) compared to the peer average (7.1x).

Price to Sales Ratio vs Industry

How does 0QNA's PS Ratio compare vs other companies in the GB Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.8.0x19.6%
0QNA Basilea Pharmaceutica
 3.4x6.0%US$572.93m
GNS Genus
1.7x3.5%US$1.43b
OXB Oxford Biomedica
4.6x21.2%US$573.21m
0QNA 3.4xIndustry Avg. 8.0xNo. of Companies7PS020406080100+
7 CompaniesEstimated GrowthMarket Cap
Industry Avg.8.0x37.3%
0QNA Basilea Pharmaceutica
 3.4x20.1%US$572.93m
No more companies

Price-To-Sales vs Industry: 0QNA is good value based on its Price-To-Sales Ratio (3.4x) compared to the European Biotechs industry average (8x).

Price to Sales Ratio vs Fair Ratio

What is 0QNA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0QNA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.4x
Fair PS Ratio1.5x

Price-To-Sales vs Fair Ratio: 0QNA is expensive based on its Price-To-Sales Ratio (3.4x) compared to the estimated Fair Price-To-Sales Ratio (1.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0QNA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 41.55
CHF 77.25
+85.9%
31.6%CHF 120.00CHF 52.00n/a6
Nov ’25CHF 43.55
CHF 74.87
+71.9%
35.7%CHF 120.00CHF 44.20n/a6
Oct ’25CHF 45.60
CHF 73.20
+60.5%
32.8%CHF 110.00CHF 44.20n/a6
Sep ’25CHF 46.20
CHF 72.37
+56.6%
32.0%CHF 110.00CHF 44.20n/a6
Aug ’25CHF 39.95
CHF 71.20
+78.2%
30.5%CHF 105.00CHF 44.20n/a6
Jul ’25CHF 39.40
CHF 71.20
+80.7%
30.5%CHF 105.00CHF 44.20n/a6
Jun ’25CHF 43.65
CHF 70.58
+61.7%
31.9%CHF 105.00CHF 40.50n/a6
May ’25CHF 39.50
CHF 70.58
+78.7%
31.9%CHF 105.00CHF 40.50n/a6
Apr ’25CHF 37.65
CHF 69.08
+83.5%
30.6%CHF 105.00CHF 40.50n/a6
Mar ’25CHF 35.15
CHF 69.08
+96.5%
30.6%CHF 105.00CHF 40.50n/a6
Feb ’25CHF 33.05
CHF 64.38
+94.8%
24.7%CHF 85.00CHF 40.50n/a4
Jan ’25CHF 35.85
CHF 70.70
+97.2%
26.5%CHF 91.00CHF 40.50n/a5
Dec ’24CHF 34.95
CHF 75.68
+116.5%
19.8%CHF 91.00CHF 57.70n/a4
Nov ’24CHF 35.30
CHF 73.28
+107.6%
20.1%CHF 91.00CHF 52.00CHF 43.556
Oct ’24CHF 41.65
CHF 70.44
+69.1%
21.7%CHF 91.00CHF 52.00CHF 45.607
Sep ’24CHF 48.10
CHF 70.44
+46.4%
21.7%CHF 91.00CHF 52.00CHF 46.207
Aug ’24CHF 43.73
CHF 70.44
+61.1%
21.7%CHF 91.00CHF 52.00CHF 39.957
Jul ’24CHF 42.13
CHF 67.18
+59.5%
21.0%CHF 91.00CHF 52.00CHF 39.406
Jun ’24CHF 45.98
CHF 67.18
+46.1%
21.0%CHF 91.00CHF 52.00CHF 43.656
May ’24CHF 42.55
CHF 72.07
+69.4%
20.8%CHF 91.00CHF 52.00CHF 39.506
Apr ’24CHF 50.33
CHF 74.80
+48.6%
18.4%CHF 91.00CHF 52.00CHF 37.655
Mar ’24CHF 52.30
CHF 68.98
+31.9%
26.2%CHF 91.00CHF 39.90CHF 35.156
Feb ’24CHF 49.00
CHF 73.82
+50.6%
34.7%CHF 120.00CHF 39.90CHF 33.056
Jan ’24CHF 45.85
CHF 69.15
+50.8%
26.2%CHF 91.00CHF 39.90CHF 35.856
Dec ’23CHF 49.32
CHF 68.58
+39.0%
28.9%CHF 91.00CHF 39.90CHF 34.955
Nov ’23CHF 46.69
CHF 74.48
+59.5%
34.4%CHF 120.00CHF 39.90CHF 35.306

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Regeneron Pharmaceuticals

US$81.2b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$742.70

7D

-0.8%

1Y

-8.6%

hVIVO

UK£146.3m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.22

7D

-1.1%

1Y

6.4%

Hikma Pharmaceuticals

UK£4.3b

Develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products.

HIKL

UK£19.41

7D

4.0%

1Y

12.9%